This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk00: Good day, and thank you for standing by, and welcome to Kean Biotech Q3 2023 Financial Results. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded. If you would like to ask any questions, you can send an email to Mark Edwards, CEO of Kean, at medwards at keenbiotech.com, or you can call Mark Edwards at 514-910-6991. I would like to introduce your host for today's call, Nicole Sendi, Investor Relations. Please go ahead.
spk01: Thank you, Operator. Good afternoon and welcome everyone to CAEN Biotech's quarterly earnings conference call. We are delighted to have you join us today. This call will cover CAEN's financial and operating results for the third quarter of 2023, along with a discussion of some of our recent highlights and goals for 2023 and beyond. Before we begin our formal remarks, I would like to remind everyone that some of the statements on this conference call contain certain forward-looking information and statements within the meaning of securities law, which may not be based on historical fact, including without limitation statements containing the words believes, should, may, plan, will, estimate, predict, continue, anticipates, potential, intends, expects, or other similar expressions. Such forward looking statements also involve known and unknown risks, uncertainties, and other factors that may cause the actual results, events, or developments to be materially different from any future results, events, or developments expressed or implied by such forward looking statements. Such factors include, among others, the company's stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market the company's products, the ability to protect its intellectual property, and dependence upon collaborative partners. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements are made as of the date hereof, and the company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events, or developments. I will now hand the call over to Chief Financial Officer Ray Dupuis. Please go ahead, Ray.
spk03: Thank you, Nicole. Before I turn the call over to Mark for an provide a brief update on our third quarter 2023 financial results. To streamline things, all the numbers that I will mention have been rounded and are therefore approximate. The following figures are all in Canadian dollars. Revenue from products and services for the three months ended September 30th, 2023 was $549,000, an increase of 29% from $426,000 current period. Royalty and license revenue for the three months end of September 30th, 2023 was $169,000, an increase of 16% compared to $145,000 in the three months end of September 30th, 2022. This increase is due mainly to incremental license revenue in the current period associated with the Scouts Honor License and Distribution Agreement, which the company signed earlier in the year. Total revenue for the three months ended September 30th, 2023 was $718,000, an increase of 26% compared to $572,000 in the three months ended September 30th, 2022. Gross profit for the third quarter of 2023 was $315,000, an increase of 17% were $1,513,000, an increase of 35% compared to $1,121,000 for the three months ended September 30th, 2022. The increase is due mainly to higher non-cash long-term incentive expense and legal expenses related to both the company's private placement offering and amendments to its credit facility recorded in the current period, LOSS FOR THE THIRD QUARTER OF 2023 WAS $1,198,000, AN INCREASE OF 41% COMPARED TO A LOSS OF $852,000 FOR THE QUARTER END OF SEPTEMBER 30, 2022. CASH AT SEPTEMBER 30, 2023 WAS $1,623,000 COMPARED TO $1,105,000 AT DECEMBER one million of financing from its lender, Pivot Financial. With that, I will now turn the call over to Mark.
spk02: Thank you, Ray. Thank you, Nicole. Before I begin, I have to apologize for our listeners. As Ray and I are traveling today, so we have recorded our remarks. If you do have any questions, please do not hesitate to reach out to us at ir at canebiotech.com. I'd like to start my remarks by welcoming Dr. John Coleman to our board of directors. I had the pleasure of spending the day with him yesterday at our Q3 board meeting. We're looking forward to working with John and further benefiting from his experience, both as a scientist and as a successful biotech CEO, as cane enters the next stage of its growth. Our strategic review of Stem Animal Health is making good progress and I look forward to reporting on the positive outcome of that review in the near future. Stem is a great company built on a patented and proven technology with multiple licensing agreements and growing revenues. I also want to thank Pivot Financial for their continued support as we work through this strategic review. With regards to our newly rebranded Revive antimicrobial hydrogel, Scale-up manufacturing is progressing on schedule with our manufacturing partner. In the meantime, we're making close to 2,000 ounces a month in-house for our commercial partner, Progenicare. We recently introduced the new name and branding to practitioners at the Symposium on Advanced Wound Care, where Revive was very well received. The number of practitioners that signed up for our evaluation program significantly exceeded our expectations. In the coming weeks, we'll continue to introduce Revive to Practitioners at the Innovations in Wound Healing Conference as well as at the John A. Boswick Burn Symposium where Dr. Greg Schultz has an accepted abstract. Turning to Dispersin B, we're making good progress towards getting FDA approval of our Dispersin B wound gel clinical trial. So all in all, we're laying the foundation for 2024 to be a transformative year for Kane Biotech, and I'm very excited for what the future holds. I apologize once again for not being available on the call for questions. Please do not hesitate to reach out at ir.kanebiotech.com.
spk00: This concludes today's conference call. Thank you for participating. You may now disconnect.
Disclaimer